To further understand how alterations in the PRKDC gene correlated with response to immune checkpoint inhibition, we analyzed data from three melanoma clinical trials utilizing PD-1/CTLA-4 therapy (2, 33, 34) and found that a higher percentage of patients with altered (mutations, deletions, amplifications) PRKDC demonstrated superior responses to immune checkpoint inhibition (Figure 6D). Here, CTLA4 is linked to melanoma.